Business
Interim Results Replacement
Interim Results Replacement.
About this update from Futura Medical Plc
[{"type":"text","content":"\n \nRNS Number : 4068R Futura Medical PLC 11 September 2014 \n \n\nThe following replaces the announcement released 11 September 2014 at 07.00 (RNS No. 3648R). \n \nThe announcement did not include full financial tables. The financial tables are now included below in the amended announcement. All other information remains unchanged. \n \nThe full amended text appears below.\n \n \nFutura Medical plc\n(\"Futura\" or the \"Company\")\n \nInterim Results for the six months ended 30 June 2014\n \nFutura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce its interim results for the six months ended 30 June 2014.\n \n \nHighlights\n \n· Significant evolution in Futura's strategy following a £12 million fundraising in March 2014 allowing the Company to build further value in its product pipeline prior to out-licensing through robust clinical data and regulatory work\n\n· CSD500 - Condom containing an erectogenic gel. Major commercial progress with initial launch anticipated later this year under the Futura-owned brand Blue Diamond™\n \n· MED2002 - Topical treatment for erectile dysfunction. Protocol for a Phase II/III clinical study nearing finalisation and planning under way to launch the product initially as a special product in 2015\n \n· PET500 - Topical spray for enhanced performance. Early stage of commercial availability throughout the USA under the Ansell brand EPIC® \n \n· Pain Relief Portfolio - Clinical trial to begin shortly with headline results expected in H1 2015\n \n· Net loss of £1.45 million in the period (H1 2013: net loss £0.88 million) \n \n· Cash resources of £11.21 million at 30 June 2014 (30 June 2013: £2.12 million) to fund Futura through key value inflexion points across its product portfolio and to support out-licensing discussions\n \n \nJames Barder, Futura's Chief Executive, said: \"We have made significant progress in the year to date and are close to starting clinical trials with the pain relief portfolio and MED2002. We ar...